We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Avoiding adverse events with dabigatran by careful selection of eligible patients.
- Authors
Baker, Ross I.; Harper, Paul; McLintock, Claire
- Abstract
The article discusses the careful selection of eligible patients to avoid adverse events with dabigatran. Dabigatran is the first oral anticoagulant for embolism prevention in people with non-valvular atrial fibrillation (AF). It has been approved in Australia and New Zealand based on the results of the Randomized Evaluation of Long-term Anticoagulant Therapy study. The study distributed patients with AF and at same risk of stroke and bleeding to therapy with warfarin and dabigatran.
- Subjects
PATIENTS; ANTICOAGULANTS; EMBOLISMS; ATRIAL fibrillation
- Publication
Medical Journal of Australia, 2012, Vol 196, Issue 7, p431
- ISSN
0025-729X
- Publication type
Editorial
- DOI
10.5694/mja11.11268